DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-408/S-033

Merck & Co., Inc.
Attention: Jeffrey R. Tucker, M.D.
Regulatory Affairs, Domestic
Merck Research Laboratories
Sumneytown Pike
BLA-20
P.O. Box 4
West Point PA 19486

Dear Dr. Tucker:

Please refer to your supplemental new drug application dated October 16, 2003, received October 17, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Trusopt (dorzolamide hydrochloride ophthalmic solution) 2%.

We acknowledge receipt of your submissions dated November 3, 2003, and April 9, 2004.

This supplemental new drug application provides for revisions in the label to reflect the safe and effective use of Trusopt (dorzolamide hydrochloride ophthalmic solution) 2% in pediatric patients with elevated intraocular pressure.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling text for the package insert, as submitted on April 9, 2004.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated **"FPL for approved supplement NDA 20-408/S-033."** Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Anti-Inflammatory, Analgesic, and Ophthalmic Drug products, HFD-550 and two copies of both the promotional materials and the package insert(s) directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Nancy Halonen, Regulatory Project Manager, at (301) 827-2199.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.
Deputy Director
Division of Anti-Inflammatory, Analgesic,
and Ophthalmic Drug products, HFD-550
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure:

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Wiley Chambers
4/15/04 09:48:56 AM